Osaka, Japan – A groundbreaking study from Osaka City University Graduate School of Medicine has unveiled a compelling new hypothesis suggesting a direct link between type 2 diabetes and the development of Alzheimer’s disease (AD). For the first time, researchers have demonstrated that amyloid-beta (Aβ) peptides, long associated with Alzheimer’s pathology in the brain, are also secreted by peripheral organs and play a regulatory role in insulin secretion, thereby influencing blood glucose clearance. This discovery, published in the prestigious journal Proceedings of the National Academy of Sciences (PNAS), not only redefines our understanding of Aβ’s origins but also carries significant implications for the diagnosis of Alzheimer’s disease.
For nearly a decade, Professor Takami Tomiyama and his dedicated research team have been meticulously investigating the complex interplay between Aβ, glucose metabolism, and neurological disorders. Their extensive work, spanning approximately 11 years, challenges the long-held assumption that blood Aβ solely reflects brain pathology. Instead, their findings point to a dynamic system where peripheral tissues actively contribute to circulating Aβ levels, influencing systemic metabolic processes.
The Elusive Link Between Diabetes and Alzheimer’s
The association between type 2 diabetes and an increased risk of developing Alzheimer’s disease has been an established epidemiological observation for years. However, the precise biological mechanisms underpinning this connection have remained largely elusive. Alzheimer’s disease is characterized by the aberrant accumulation of Aβ plaques in the brain, a process believed to be central to neuronal dysfunction and cognitive decline. Aβ is generated through the enzymatic cleavage of the amyloid precursor protein (APP) by beta-secretase (BACE1) and gamma-secretase. Crucially, the expression of APP and these secretases is not confined to the brain; they are present in numerous tissues throughout the body. This widespread expression has historically made it difficult to pinpoint the exact origin of Aβ found in the bloodstream, leading to its common use as a potential surrogate marker for brain amyloidosis.
Professor Tomiyama’s team was driven by two key unanswered questions: "First, as AD is caused by the accumulation of Aβ in the brain, it is thought that Aβ levels in the blood reflect the pathology in the brain and are currently used as a diagnostic marker. However, Aβ is generated from the amyloid precursor protein (APP) through the function of two enzymes, β- and γ-secretases, and this mechanism is expressed in many of the body’s peripheral tissues, not only in the brain, causing the origin of blood Aβ to remain unknown. Second, epidemiological studies have shown type 2 diabetes to be a strong risk factor for the development of AD, yet the mechanism linking these two diseases has eluded researchers as well," Professor Tomiyama explained in an interview.
Tracing the Origin: Peripheral Secretion of Amyloid-Beta
Early clues emerged from Professor Tomiyama’s prior research involving mice. In experiments where mice were injected with glucose, they observed a transient spike in both glucose and insulin levels, peaking around 15 minutes. Intriguingly, blood Aβ levels followed with a noticeable delay, reaching their peak between 30 and 120 minutes post-injection. Further supporting this line of inquiry, previous studies had demonstrated that oral glucose administration could increase blood Aβ levels in individuals with Alzheimer’s disease. These observations collectively fueled the hypothesis that Aβ detected in the blood might be secreted from peripheral tissues that are sensitive to glucose and insulin, and that this peripherally derived Aβ could play a role in glucose and insulin metabolism.
To systematically investigate this hypothesis, the researchers conducted a series of experiments using mice. Initially, they examined the impact of glucose and insulin on blood Aβ levels in mice that had been fasted for 16 hours. Blood samples were collected at various time points after glucose injection, revealing the expected transient increases in glucose, insulin, and, crucially, Aβ, thus confirming their earlier observations.
The next critical step was to ascertain the functional impact of Aβ on insulin secretion. For this, they utilized APP knockout mice, which are incapable of producing their own Aβ. These mice were administered both Aβ and glucose. The results were significant: the presence of Aβ demonstrably suppressed the glucose-stimulated surge in insulin levels. This finding strongly suggested that Aβ itself acts as a modulator of insulin release.
Identifying the Sources: Pancreas, Liver, and Adipose Tissue Emerge
With the understanding that blood Aβ levels fluctuate in response to glucose and insulin, and that Aβ influences insulin secretion, the team focused on identifying the specific peripheral tissues responsible for secreting Aβ. Their investigation centered on the pancreas, adipose tissue, skeletal muscle, liver, and kidneys – organs known to be involved in glucose and insulin metabolism. By isolating these tissues and exposing them to glucose and insulin in vitro, they measured the resultant Aβ secretion.
The results were conclusive: the pancreas secreted Aβ when stimulated by glucose, while adipose tissue, skeletal muscle, and liver released Aβ in response to insulin. The kidneys, which are not directly involved in glucose or insulin metabolism, showed no significant Aβ secretion under either stimulus. Furthermore, when both glucose and Aβ were added to isolated pancreatic tissue, they observed a marked suppression of insulin secretion. This provided direct evidence that Aβ, secreted from the pancreas under glucose stimulation, can feedback to inhibit insulin release.
Cellular Localization and the Role of Organokines
To gain a deeper insight into the cellular mechanisms at play, the researchers employed immunohistochemistry to pinpoint the location of Aβ within these peripheral tissues. In pancreatic tissue, Aβ was found exclusively within insulin-producing beta (β) cells. Interestingly, following glucose injections, the β-cells of mice showed reduced immunoreactions to both Aβ and insulin. This suggests that during fasting periods, Aβ and insulin are stored within β-cells and are released into circulation when stimulated by glucose.
The investigation extended to other insulin-targeted organs. Tissue sections were immunostained for Aβ and organokines – bioactive substances specific to each organ. The study found Aβ co-localized with organokines in all tested tissues, and notably, with reduced immunoreactions when stimulated by insulin. Professor Tomiyama elaborated, "Our findings suggest that Aβ and organokines are stored during periods of fast and released into circulation when stimulated with insulin." He added, "A comprehensive understanding of the organokine action of peripheral Aβ is something we hope to develop in future work."
Implications for Alzheimer’s Diagnosis and Diabetes Management
The implications of these findings are far-reaching, particularly concerning the diagnostic utility of blood Aβ levels for Alzheimer’s disease. The study clearly demonstrates that blood Aβ levels are dynamic and significantly influenced by dietary intake and metabolic state. "This work was finally published after about 11 years," stated Professor Tomiyama. "It is not only an academic discovery, but also has implications in how we diagnose AD."
The research suggests that using blood Aβ as a standalone diagnostic marker for AD without considering these metabolic influences could lead to inaccurate interpretations. "Our data suggest that as blood Aβ levels fluctuate significantly with diet, special care should be taken when diagnosing AD with blood Aβ," Professor Tomiyama concluded. This means that factors like recent meals, fasting status, and underlying metabolic conditions such as diabetes must be carefully considered when interpreting blood Aβ measurements in the context of AD diagnosis. Researchers may need to standardize testing protocols, potentially requiring blood samples to be taken during a fasting state, to minimize variability and improve the reliability of these biomarkers.
A New Perspective on the Diabetes-Alzheimer’s Connection
Beyond diagnostic considerations, the study offers a compelling biological explanation for the heightened risk of Alzheimer’s disease in individuals with type 2 diabetes. In diabetic individuals, persistently elevated blood glucose and insulin levels likely lead to chronic elevation of peripheral Aβ secretion. This elevated circulating Aβ could, in turn, disrupt the delicate balance of Aβ transport across the blood-brain barrier and interfere with the glymphatic system, the brain’s waste clearance mechanism. If Aβ cannot efficiently exit the brain or is produced excessively in response to systemic metabolic dysregulation, it could contribute to the amyloid plaque accumulation characteristic of AD.
This research opens new avenues for therapeutic interventions. By targeting the peripheral production or secretion of Aβ, or by modulating its interaction with insulin signaling pathways, it may be possible to not only improve glycemic control but also mitigate the risk of neurodegenerative diseases like Alzheimer’s. Future research will likely focus on understanding the precise molecular pathways involved in the co-storage and release of Aβ and organokines, and on exploring the therapeutic potential of modulating these processes. The long-term vision is to develop strategies that address both metabolic health and brain health, offering a more holistic approach to preventing and managing age-related diseases. The comprehensive nature of this 11-year investigation underscores the power of persistent scientific inquiry in unraveling complex biological mysteries and paving the way for significant advancements in human health.